Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BARDA To Fund Pediatric Development Of Cempra’s Solithromycin

This article was originally published in The Pink Sheet Daily

Executive Summary

Antibiotic-focused biotech can earn $58 million over five years under the government contract, which provides for testing of the novel macrolide in pediatric indications and for protection against bioterror-threat pathogens.

You may also be interested in...



Solithromycin Proves Safe, Makes Cempra A Deal Target

The antibiotic showed promising results in a late-stage study of the oral formulation, setting the company up as a potential target for acquirers and partnering opportunities – though for now it is signaling its intent to go it alone.

Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin

GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.

Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin

Law has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel